Kenneth A. Berlin
The FDA has placed a partial clinical hold on the phase III AIM2CERV trial (NCT02853604) evaluating the use of axalimogene filolisbac (AXAL) in patients with high-risk locally advanced cervical cancer, according to Advaxis, Inc., the developer of the investigational immunotherapy agent.1
- Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests [news release]. Advaxis; January 23, 2019. https://bit.ly/2S3GMNa. Accessed January 24, 2019.
- Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV). ClinicalTrials.gov website. clinicaltrials.gov/ct2/show/NCT02853604?term=NCT02853604. Published August 3, 2016. Updated April 12, 2018. Accessed January 24, 2019.
... to read the full story